Large multinational pharma companies publicly express concern about the threat from China's biopharma sector. Simultaneously, these same companies are investing billions, actively integrating China into the global ecosystem and contradicting their own zero-sum game narrative.

A disconnect exists between the public rhetoric of U.S. pharma leaders, who frame China's growing biotech sector as a threat, and their corporate actions. These same companies are investing heavily in Chinese R&D and manufacturing, revealing a dual strategy of public caution and private commitment to integrating China into the global biopharma ecosystem.

Contrary to lingering Western perceptions, the idea that data from Chinese biotechs is poor or that the country doesn't produce real innovation is outdated and incorrect. China's life sciences sector is now increasingly sophisticated and innovative, fueled by significant government investment, making it a critical global player that cannot be underestimated.

Driven by significant government investment, China is rapidly becoming a leader in biotech R&D, licensing, and outsourcing. This shift is a top-of-mind concern for US biotech and pharma executives, with China now involved in a majority of top R&D licensing deals.

Instead of traditional regional HQs, firms should adopt a "capability-first" model. This involves strategically placing functions where excellence exists: basic science in Japan, clinical scale in China, and biologics in Korea. This creates a more efficient, interconnected global R&D engine, breaking from geography-based silos.

A Boehringer Ingelheim executive noted a key differentiator of Korean biotechs: they enter initial partnership discussions with a well-defined strategy and understanding of their needs. This "readiness to partner" accelerates deal-making and demonstrates a higher level of business sophistication compared to many global counterparts.

The future biotech landscape is not US vs. China, but a "multipolar" world where savvy companies operate as "hybrid biotechs." They will selectively build bridges, cherry-picking talent, capabilities, and operational models across the US, Europe, and China to accelerate development.

Contrary to common belief, a BioCentury analysis revealed that two-thirds of out-licensing deals from Asian innovators were with Western biotechs, not large multinational pharmaceutical corporations. This indicates a significant trend of smaller Western companies actively sourcing innovation from Asia.

The narrative of China as an innovation 'threat' in biopharma may be a deliberate strategy to spur action in the U.S. By creating a sense of urgency and competition, reminiscent of the U.S.-Soviet superpower struggle, the industry may be attempting to mobilize investment and political will, even if the framing is seen as unfortunate.